Biogen vs Thermo Fisher Scientific

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (78 vs 79)
Biogen logo

Biogen

LeaderHealthcare Tech

Enterprise

Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.

AI VisibilityBeta
Overall Score
B78
Category Rank
#43 of 596
AI Consensus
72%
Trend
stable
Per Platform
ChatGPT
82
Perplexity
81
Gemini
83

About

Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.

Full profile
Thermo Fisher Scientific logo

Thermo Fisher Scientific

LeaderHealthcare Tech

Enterprise

Thermo Fisher (TMO) reported $42.9B revenue in FY2024, down 1% YoY. World's #1 life sciences company. Serves pharma, biotech, labs globally. ~100,000 employees. HQ: Waltham, MA.

AI VisibilityBeta
Overall Score
B79
Category Rank
#23 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
81
Perplexity
79
Gemini
85

About

Thermo Fisher Scientific Inc. is the world's largest life sciences company, providing analytical instruments, reagents, consumables, software, and services to researchers, healthcare organizations, and industrial companies. Headquartered in Waltham, Massachusetts, Thermo Fisher was formed through the 2006 merger of Thermo Electron and Fisher Scientific and has since grown aggressively through acquisitions. The company reported revenues of $42.9B in FY2024, slightly down year-over-year after exceptional COVID-related revenue in 2021–2022.

Full profile

AI Visibility Head-to-Head

78
Overall Score
79
#43
Category Rank
#23
72
AI Consensus
80
stable
Trend
stable
82
ChatGPT
81
81
Perplexity
79
83
Gemini
85
72
Claude
77
76
Grok
77

Key Details

Category
Enterprise
Enterprise
Tier
Leader
Leader
Entity Type
company
company

Capabilities & Ecosystem

Integrations

Both integrate with
Biogen is classified as company. Thermo Fisher Scientific is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.